Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.

Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...

The project signals growing confidence in Dubai's commercial real estate sector, which has seen strong leasing activity and ...

Objective To quantify changes in inequalities in uptake of childhood vaccination during a period of steadily declining overall childhood vaccination rates in England. Design Longitudinal study.

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

GSK respiratory/immunology research and development global head Kaivan Khavandi stated: “Working with Relation enables us to ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), BP p.l.c. (BP) ...

Inequalities in childhood vaccination are widening in England, with uptake rates of five key vaccines consistently lower in ...